Shanghai Henlius Biotech, Inc. will showcase the latest clinical data of its anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab) and innovative anti-HER2 monoclonal antibody HLX22 at the 2025 ASCO Gastrointestinal Cancers Symposium. The presentations will cover updated efficacy and safety profiles of these treatments in various gastrointestinal and lung cancer indications.
The FDA has approved Tagrisso (osimertinib) for adults with unresectable Stage III EGFR-mutated non-small cell lung cancer (NSCLC) after platinum-based chemoradiation therapy.
Henlius' HLX22, combined with trastuzumab and chemotherapy, shows improved survival and antitumor response in HER2-positive gastric/gastroesophageal junction (G/GEJ) cancer patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.